Culture of hematopoietic stem cells purified from murine bone marrow.

Abstract:

:The results of the Y-chromosome in situ hybridization experiments, the MRA assessment, and the long-term production of CFU-GM in vitro indicate that our protocol to sort low density WGA+, 15/1.1-, Rh123 dull cells enriches about 200-fold for PHSC. Assays for spleen colony formation (CFU-S) and radioprotection (30-day survival) were shown to be unspecific for PHSC, and, therefore, we lack a quantitative PHSC assay. The absolute number of PHSC in the bone marrow is not known any more, the purity of our sorted population likewise is unknown. Long-term repopulating cells (PHSC) could be separated from short-term repopulating ones by using Rh123 staining. The short-term repopulating cells (Rh123 bright) provided sufficient offspring to protect lethally irradiated mice until endogenous PHSC could reconstitute hematopoiesis. These cells are therefore of interest for bone marrow transplantation, because they provide radioprotection without long-term repopulation and graft-versus-host disease. For gene therapy these cells are of limited use, and PHSC with extensive replication are needed. The PHSC were not cultured successfully. Less than 15% of the sorted Rh123 dull cells responded in semisolid or liquid cultures in the presence of growth factors. Proliferation without differentiation was not observed. This may indicate that the right growth factor has not been found yet. On the other hand, about 30% of the cells responded in stromal layers of long-term bone marrow cultures and prolonged CFU-GM production and cobblestone area formation were observed there, suggesting that cell-cell contact and adherence molecules play a regulatory role in PHSC replication.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Visser JW,de Vries P,Hogeweg-Platenburg MG,Bayer J,Schoeters G,van den Heuvel R,Mulder DH

subject

Has Abstract

pub_date

1991-04-01 00:00:00

pages

117-25

issue

2

eissn

0037-1963

issn

1532-8686

pii

0037-1963(91)90074-E

journal_volume

28

pub_type

杂志文章,评审
  • Mismatched unrelated donor transplantation.

    abstract::There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.07.003

    authors: Petersdorf EW

    更新日期:2016-10-01 00:00:00

  • Evaluation of Macrocytic Anemias.

    abstract::Macrocytic anemia, defined as a mean cell volume (MCV) ≥100 fL in adults, has a narrow differential diagnosis that requires evaluation of the peripheral blood smear as well as additional laboratory testing taken in conjunction with clinical information that includes patient history and physical examination findings. T...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2015.06.001

    authors: Green R,Dwyre DM

    更新日期:2015-10-01 00:00:00

  • Cyclic neutropenia.

    abstract::Cyclic neutropenia is a rare hematologic disorder, characterized by repetitive episodes of fever, mouth ulcers, and infections attributable to recurrent severe neutropenia. Fluctuations in blood cells are due to oscillatory production of cells by the bone marrow. Recent genetic, molecular, and cellular studies have sh...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.31917

    authors: Dale DC,Bolyard AA,Aprikyan A

    更新日期:2002-04-01 00:00:00

  • Perspectives on the future of chronic myeloid leukemia treatment.

    abstract::Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90116-7

    authors: Appelbaum FR

    更新日期:2001-07-01 00:00:00

  • Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

    abstract::The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.10.004

    authors: Richardson P

    更新日期:2005-10-01 00:00:00

  • The potential role of new therapies in deep-vein thrombosis prophylaxis.

    abstract::The value of prophylaxis against venous thromboembolism (VTE) is increasingly accepted in most surgical specialties, although the potential reduction in fatal pulmonary embolism has recently been questioned. The burden of VTE in hospital patients nevertheless remains high, partly attributable to underuse of thrombopro...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2001.25188

    authors: Wille-Jørgensen P

    更新日期:2001-04-01 00:00:00

  • A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.

    abstract::This phase I trial of idarubicin (IDA) was conducted in 32 patients with acute leukemia and chronic myelogenous leukemia (CML) in blastic crisis (CML/BC) who either had failed to achieve a complete remission (CR) after initial induction therapy or had relapsed after CR. IDA was administered at dosages ranging from an ...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章,评审

    doi:

    authors: Tamura K

    更新日期:1996-10-01 00:00:00

  • Treatment strategies for Hodgkin's disease.

    abstract::Over the past 2 decades, treatment of Hodgkin's disease has evolved considerably through innovations in the management of various stages. The impact of various treatments on the 5-, 10-, and 15-year results is being balanced against delayed morbidity, such as organ damage and second malignancies, produced by the inten...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Bonadonna G,Santoro A,Viviani S,Valagussa P

    更新日期:1988-04-01 00:00:00

  • The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation.

    abstract::The prolonged and severe myelosuppression associated with high-dose chemotherapy and autologous bone marrow transplantation is a major causative factor in patient morbidity and mortality resulting from infection and other causes. The recent molecular cloning, in vitro expression, and formulation of recombinant human c...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Peters WP

    更新日期:1989-04-01 00:00:00

  • The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.

    abstract::Untreated anemia is common in cancer patients. Previous studies have demonstrated that both the existence of cancer and treatment with chemotherapy can suppress the normal endogenous erythropoietic response to anemia, making some cancer patients transfusion cadidates. In placebo-controlled phase III studies, administr...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Glaspy J

    更新日期:1997-07-01 00:00:00

  • Fc receptor blockade and immune thrombocytopenic purpura.

    abstract::Inhibition of antibody-coated platelet destruction in patients with immune thrombocytopenic purpura (ITP) is a well-known mechanism of treatment effect. A number of interventions that would ameliorate the thrombocytopenic effect of ITP patient plasma when infused into normal recipients were demonstrated in 1965. Subse...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90104-5

    authors: Bussel JB

    更新日期:2000-07-01 00:00:00

  • Next generation sequencing in hematolymphoid neoplasia.

    abstract::Large scale sequencing projects over the past 2 decades have led to the identification of many common genomic alterations in hematolymphoid neoplasms, some of which with diagnostic, therapeutic, and prognostic implications [1-3]. Although these alterations can be tested individually with high sensitivity and specifici...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2018.05.006

    authors: Kuo FC

    更新日期:2019-01-01 00:00:00

  • Mismatched unrelated alternative donors for hematological malignancies.

    abstract::For the majority of hematologic malignancies allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option. Sibling donors have been the standard for adult patients. Since there is not a suitable family donor for all patients, the need for alternative donors for HCT is great. Fortunately, t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.01.009

    authors: Sebastian Schäfer H,Finke J

    更新日期:2016-04-01 00:00:00

  • Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

    abstract::Imatinib (Gleevec) (formerly STI571) competitively targets the adenosine 5-triphosphate (ATP) binding site of the kinase domain of ABL and was recently approved for the treatment of chronic myeloid leukemia (CML). Point mutations occurring in the kinase domain of BCR-ABL have been identified as a cause of imatinib res...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50046

    authors: Roche-Lestienne C,Preudhomme C

    更新日期:2003-04-01 00:00:00

  • Reducing mortality associated with immediate treatment complications of adult leukemias.

    abstract::Analysis of data from 806 patients with newly diagnosed adult acute myelocytic leukemia (AML) (not including acute promyelocytic leukemia [APL] patients) treated at M.D. Anderson Cancer Center from 1995 through 1999 indicated that among patients entering a particular week of induction therapy, mortality rates were 6%,...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1016/s0037-1963(01)90042-3

    authors: Estey E

    更新日期:2001-10-01 00:00:00

  • Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery.

    abstract::In previous studies, treatment with epoetin alfa facilitated preoperative donation of autologous blood (AB). However, some patients may not be able to donate sufficient AB to meet their surgical blood requirements when the time to surgery is short. In this multicenter, double-blind, placebo-controlled study, the abili...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Tryba M

    更新日期:1996-04-01 00:00:00

  • Improving CAR T-cells: The next generation.

    abstract::The introduction of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL) has dramatically altered the landscape of treatment options available to children and adults with ALL. With complete remission induction rates exceeding 70% in most trials and FDA approval of one CD19 CAR T-cell co...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.07.002

    authors: Marple AH,Bonifant CL,Shah NN

    更新日期:2020-07-01 00:00:00

  • Pentostatin for the treatment of indolent lymphoproliferative disorders.

    abstract::Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.12.005

    authors: Ho AD,Hensel M

    更新日期:2006-04-01 00:00:00

  • Copper deficiency in humans.

    abstract::Copper is an essential trace element that is required for a number of enzymes which are necessary for normal metabolic function. Metabolic balance studies have demonstrated that daily copper losses are approximately 1.3 mg/day. In order to remain in copper balance, the average adult male must consume a diet which cont...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Williams DM

    更新日期:1983-04-01 00:00:00

  • Biology of chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) is a clonal proliferation of mature-appearing, but maturationally immature B cells; T cells are rarely involved. Most data suggest that CLL cells are frozen at an early step in maturation; this can be overcome by several techniques such as in vitro incubation with tumor promotors. Al...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Gale RP,Foon KA

    更新日期:1987-10-01 00:00:00

  • Immune dysregulation in immune thrombocytopenia.

    abstract::Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.011

    authors: Yazdanbakhsh K,Zhong H,Bao W

    更新日期:2013-01-01 00:00:00

  • Anemia of chronic disease.

    abstract::Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.06.006

    authors: Gangat N,Wolanskyj AP

    更新日期:2013-07-01 00:00:00

  • Thrombosis and anticoagulation.

    abstract::Most of the major advances in thrombosis research have occurred in the last 50 years, reflecting progress in biomedical sciences and clinical trials methodology. Improved understanding of the mechanisms of thrombogenesis has led to the discovery of a plethora of new antithrombotic agents that target many of the key st...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章,评审

    doi:

    authors: Hirsh J,Weitz JI

    更新日期:1999-10-01 00:00:00

  • Leukocyte-endothelial cell interactions.

    abstract::Mechanisms that support migration of leukocytes have been studied extensively in vitro. The adhesion of neutrophils under conditions of flow at venous shear rates primarily involves members of the selectin family. E-selectin is upregulated by cytokine stimulation of endothelial cells (ECs); P-selectin is upregulated b...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith CW

    更新日期:1993-10-01 00:00:00

  • Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.

    abstract::The farnesyltransferase inhibitors (FTIs) have been shown in early clinical trials to elicit antitumor actions in a broad range of solid and hematologic malignancies. The mechanism of FTI action involves blockade of farnesyltransferase, an enzyme implicated in multiple cell-signaling pathways involved in proliferation...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.35984

    authors: Cortes JE,Kurzrock R,Kantarjian HM

    更新日期:2002-07-01 00:00:00

  • Novel agents in development for peripheral T-cell lymphoma.

    abstract::Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.014

    authors: O'Connor OA

    更新日期:2010-04-01 00:00:00

  • Who is the best donor for haploidentical stem cell transplantation?

    abstract::Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian pop...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2018.08.003

    authors: Kongtim P,Ciurea SO

    更新日期:2019-07-01 00:00:00

  • Predictive genetic variants for venous thrombosis: what's new?

    abstract::Various pathways lead to the development of venous thrombosis. Risk factors are common and can be genetic or acquired. Since the identification of factor V Leiden and prothrombin 20210 G-->A, the field of genetic epidemiology has developed rapidly and many new genetic variants have been described in the past decade. H...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.01.007

    authors: Bezemer ID,Rosendaal FR

    更新日期:2007-04-01 00:00:00

  • Assessment of treatment strategy in high-risk surgical patients.

    abstract::The risk of postoperative venous thromboembolism (VTE) is dependent on the type of surgical procedure and specific characteristics of the patient. Patients with intrinsic factors placing them at higher risk of VTE remain at high risk, even if the procedural risk is low. The identification of factors such as age, obesi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(00)90094-5

    authors: Samama MM

    更新日期:2000-07-01 00:00:00

  • Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation.

    abstract::Over the last two decades quality of life (QoL) and the social challenges of allogeneic hematopoietic stem cell transplant (allo-HSCT) survivors have been emerging as subjects of extensive research and are now considered as very important aspects in the pretransplant evaluation and management of allo-HSCT recipients. ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.004

    authors: Norkin M,Hsu JW,Wingard JR

    更新日期:2012-01-01 00:00:00